Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, presented today new preclinical data showing its DARPin T-cell engager MP0533 can induce preferential killing of cells expressing two or three tumor-associated antigens (TAAs) compared to cells expressing a single TAA. The data was disclosed in an oral presentation at the 64th Annual American Society of Hematology Meeting in New Orleans.
Related news for (MOLN)
- Molecular Partners and Orano Med Share Positive DLL3 Preclinical Data
- Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
- Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2023